Phenylethylamine biosynthesis pathway

Phenylethylamine (PEA) is an organic compound naturally produced across many species including humans. It acts as a central nervous system stimulant and functions as a trace amine neurotransmitter. The primary biosynthetic route involves enzymatic decarboxylation of the amino acid phenylalanine catalyzed mainly by aromatic-L-amino-acid decarboxylase and possibly other enzymes like DisA in some bacteria. Once formed, PEA has rapid metabolism primarily via monoamine oxidases A and B, semicarbazide-sensitive amine oxidases, among others. This rapid degradation limits its half-life but also tightly regulates its physiological effects. In addition to neurological roles, some marine bacteria produce antimicrobial compounds derived from phenethylamines indicating ecological significance beyond human biology[1][2][3][4][5]. In summary, while "Phenylethylamine biosynthesis pathway" is not itself an individual molecular target suitable for direct drug targeting classification, it encompasses important enzymatic steps producing biologically active molecules relevant both neurologically and microbiologically. Therapeutic modulation typically focuses on downstream catabolic enzymes like monoamine oxidases affecting endogenous PEA concentrations[1][2].

Other names

phenethylamine synthesisphenylalanine decarboxylation

For drugs targeting enzymes related to this pathway: Monoamine oxidase inhibitors increase endogenous phenylethylamine concentration by inhibiting its metabolism.